Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03580655 · MORE INFO

Limitations, agreements, and source contact

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · Source last updated 2026-04-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
After (a) sponsor publication of the comprehensive multi-center clinical trial results; (b) sponsor notification that the multi-center clinical trial submission is no longer planned; or (c) the 18-month anniversary of the completion or early termination of the multi-center clinical trial, the PI (institution/investigator) may publish or publicly present the study data in accordance with the provisions set forth by the sponsor.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
Compared to investigator-assessed response with its challenging interpretations of any differences in ORR by central adjudication, ORR by centrally adjudicated mIWG-MRT-ECNM criteria as assessed by the study steering committee is the most accurate and reliable evaluation of response to treatment in AdvSM.
point Of Contact
email
medinfo@blueprintmedicines.com
organization
Blueprint Medicines
phone
1-888-258-7768
title
Blueprint Medicines Medical Information
Complete source fields
certain Agreement
other Details
After (a) sponsor publication of the comprehensive multi-center clinical trial results; (b) sponsor notification that the multi-center clinical trial submission is no longer planned; or (c) the 18-month anniversary of the completion or early termination of the multi-center clinical trial, the PI (institution/investigator) may publish or publicly present the study data in accordance with the provisions set forth by the sponsor.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
Compared to investigator-assessed response with its challenging interpretations of any differences in ORR by central adjudication, ORR by centrally adjudicated mIWG-MRT-ECNM criteria as assessed by the study steering committee is the most accurate and reliable evaluation of response to treatment in AdvSM.
point Of Contact
email
medinfo@blueprintmedicines.com
organization
Blueprint Medicines
phone
1-888-258-7768
title
Blueprint Medicines Medical Information

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice